Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.
RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
Untreated or unmanaged, SVT can lead to other possibly fatal heart abnormalities. Patients are advised to practice a cardiac-friendly diet and lifestyle (low sodium, little to no caffeine or alcohol, ...
Credit: AOP Health. Rapiblyk is supplied as a lyophilized powder containing 280mg of landiolol (equivalent to 300mg of landiolol HCl) in a single-dose vial. It is intended for use in intensive care, ...
Background Inappropriate sinus tachycardia (IST) is characterized by persistent and disproportional elevation of heart rate (HR). Ivabradine has been successfully used in some patients. Methods Twenty ...
Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT)Breakthrough device designation granted for use of th ...
AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK® (landiolol) for use in pediatric patients (from birth to <18 years of age) with ...
WILMINGTON, Del., April 15, 2026--(BUSINESS WIRE)--AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK® (landiolol) for use in pediatric patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results